Most Read Articles
Stephen Padilla, 06 Aug 2020
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.

Elderly myocardial infarction patients benefit from 2 years of statins

12 Nov 2019

The use of statins is beneficial in elderly patients after their first myocardial infarction (MI) episode, particularly if medication is sustained for at least 2 years, a recent study has shown.

Researchers retrospectively assessed 9,020 elderly patients (aged 65 years) who had had their first MI episode. The primary outcome of interest was a composite between recurrent MI, cardiovascular mortality and stroke, whose occurrence was evaluated according to statin medication status. All-cause mortality was a secondary outcome.

Statin medication lasting >2 years reduced the incidence of the primary endpoint as compared to no statins in the 80-year age subgroup (adjusted hazard ratio [HR], 0.79, 95 percent confidence interval [CI], 0.62–1.02). This effect was statistically significant in participants aged 65–80 years (adjusted HR, 0.62, 95 percent CI, 0.44–0.88).

Prescriptions lasting 1–2 years, on the other hand, had no such effect in both the older and younger age subgroups (adjusted HR, 0.98, 95 percent CI, 0.75–1.29 and adjusted HR, 0.72, 95 percent CI, 0.49–1.05, respectively).

Interestingly, a statin regimen administered for less than a year yielded significant benefits for those aged 65–80 years (adjusted HR, 0.80, 95 percent CI, 0.67–0.95) and 80 years (adjusted HR, 0.51, 0.41–0.65).

Two- and <1-year courses of statin medication similarly improved all-cause mortality rates in both the older and younger age subgroups. Regimens lasting 1–2 years were not effective.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 06 Aug 2020
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.